# Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization

**Authors:** Apostolos Gkatzionis, Eleanor Sanderson, George Davey Smith, Stefan Stender, Helene Gellert‐Kristensen

PMC · DOI: 10.1111/liv.70609 · Liver International · 2026-03-19

## TL;DR

This study finds that obesity increases the risk of liver cancer mainly by causing liver scarring, called cirrhosis.

## Contribution

The study uses genetic evidence to show that cirrhosis is the main pathway through which obesity causes liver cancer.

## Key findings

- Obesity increases liver cancer risk by 1.65 times per standard deviation increase in BMI.
- The direct effect of obesity on liver cancer disappears when accounting for cirrhosis risk.
- Childhood obesity increases liver cancer risk, but this effect is explained by adult obesity when considered together.

## Abstract

While cirrhosis is a primary risk factor for hepatocellular carcinoma (HCC), a significant proportion of HCC cases attributed to metabolic dysfunction‐associated steatotic liver disease (MASLD) develop in the absence of cirrhosis. MASLD is strongly linked to obesity, a known risk factor for multiple cancers. Whether the effect of obesity on HCC is mediated via cirrhosis or other factors is unknown.

We used univariable Mendelian randomization (MR) to test the total effect of a higher body mass index (BMI), a proxy for obesity, on HCC, and multivariable MR to test the direct effect.

We estimated that the effect of BMI was a 1.65‐fold higher risk of HCC per standard deviation increase (95% confidence interval (CI): 1.28–2.12, p‐value = 1.0 × 10−5). The BMI effect became indistinguishable from zero when taking liability to cirrhosis into account with multivariable MR (odds ratio = 1.12, 95% CI: 0.84–1.50, p‐value = 0.44). We investigated additional potential pathways linking BMI to HCC—such as inflammation and type 2 diabetes—and explored the direct effect of childhood obesity on the risk of HCC. We found no direct effect of inflammation or type 2 diabetes (p‐values > 0.05). Childhood body size increased the risk of HCC (odds ratio = 1.78, 95% CI: 1.27–2.49, p‐value = 8 × 10−4), but the effect disappeared when we took adult body size into account using multivariable MR.

Cirrhosis liability is the primary mediator of the causal effect of obesity on HCC.

Obesity significantly raises the risk of liver cell cancer. Using genetic evidence, our results show that the likelihood of developing cirrhosis (scarring of the liver) mediates the entire risk of liver cell cancer seen with obesity. This suggests that preventing liver scarring is the key to stopping obesity‐related liver cell cancer and urges further investigation into alternative causes for obese patients who develop liver cell cancer without cirrhosis.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256), cirrhosis (MONDO:0005155), metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, TM6SF2 (transmembrane 6 superfamily member 2) [NCBI Gene 53345], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}, SUGP1 (SURP and G-patch domain containing 1) [NCBI Gene 57794] {aka F23858, RBP, SF4}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}
- **Diseases:** diabetes mellitus (MESH:D003920), coronary artery disease (MESH:D003324), cirrhotic (MESH:D000094724), HCC (MESH:D006528), hepatitis C virus infection (MESH:D006526), non-alcoholic fatty liver disease (MESH:D065626), diabetes mellitus type II (MESH:D003924), Obesity (MESH:D009765), death (MESH:D003643), insulin resistance (MESH:D007333), hepatitis B (MESH:D006509), inflammation (MESH:D007249), steatohepatitis (MESH:D005234), genetic diseases (MESH:D030342), MASLD-HCC (MESH:D008107), scarring of the liver (MESH:D017093), metabolic syndrome (MESH:D024821), cancer (MESH:D009369), Cirrhosis (MESH:D005355), weight-gain (MESH:D015430), metabolic dysfunction (MESH:D008659), alcohol-associated liver disease (MESH:D008108), MR (MESH:C562757)
- **Chemicals:** alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs188247550, rs739846, A1C, p.Ile148Met

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13000872/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13000872/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC13000872/full.md

---
Source: https://tomesphere.com/paper/PMC13000872